Patent Cliff Preparation and Mitigation with Source One's sourcing advisory services
ProcureCon Pharma is this week, and we are very excited to be a sponsor of this event. Source One has partnered with major pharmaceutical companies to reduce spend and optimize supply chains since its inception in 1992. This event has sparked us to consider some of the major issues facing pharma today. Most notably, the ripple effects from the patent cliff that have left many organizations reeling.
There have been many changes since big pharma’s major brands have started to go off patent. However, the most notable differences, from a procurement perspective, involve indirect spend management, increased competition, mergers and acquisitions, uptick in biopharmaceuticals and even investments into emerging markets such as Africa. The infographic below explains some of these post-patent trends and their subsequent results.